Vanderbilt Human Research Protection Program
Institutional Biosafety Committee-Human Subjects
NIH Registration Number TN00040

The IBC-HS Committee meets the third Friday of the month from 8:30 to 10:30 am. Meeting locations are subject to change. Please call the VHRPP office to confirm meeting location (322-2918).

Effective – July 1, 2021

VOTING MEMBERS (10)

Antonis Hatzopoulos, PhD - Chair

Allison Wheeler, MD - Vice-Chair

Stephen Brandt, MD

Jonathan Lehman, MD, PhD

Douglas Johnson, MD

Lori Rolando, MD, MPH

Richard DiTullio, PhD

Donna Torr, PharmD

Kimberly Towers

Rolanda Edding, MT(ASCP)

Cell and Developmental Biology

Pulmonary/Critical Care

Hematology/Oncology

Hematology/Oncology

Hematology/Oncology

Occupational Health and Safety

Biological Safety Officer

Investigational Drug Service

Community Member

Community Member/Department of Health

 

ALTERNATE MEMBERS
Ray Peebles, MD Pathology/Pediatric Oncology

Carrie Kitko, MD Pediatric Stem Cell Transplantation

Jennifer Bounds, Community Member

Brenton Harrison, Community Member

Vanderbilt’s Institutional Biosafety Committee-Human Subjects (IBC-HS) is authorized by the National Institutes of Health (NIH) to approve research projects involving the use of recombinant DNA and synthetic nucleotide research involving humans. Use the IBC application that is embedded in the IRB application and guidelines to submit proposals to the IBC-HS. If you need help in completing and IBC-HS application, contact the IRB to have the a member of the IBC-HS team to assist you.